Protocol changes can improve outcomes
Fevers in cancer patients receiving chemotherapy can indicate an infection, which may be life- threatening. Quick administration of antibiotics is critical to minimize harm, shorten hospital stays and improve patient outcomes.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
With the goal of reducing antibiotic administration delays in these patients, Cleveland Clinic researchers worked with the medical center’s Emergency Department (ED) personnel to implement several changes, including:
The researchers then studied all adult cancer patients who presented with fever at Cleveland Clinic’s ED between June 2012 and June 2013, comparing their outcomes with those of a group of cancer patients treated in the ED prior to the FN changes, and to a group of febrile cancer patients admitted directly to the hospital’s inpatient oncology service.
The investigators followed participating cancer patients for one year. Results showed that the FN protocol changes significantly decreased the time it took affected patients to receive antibiotics and shortened their hospital stays compared with the other groups.
Read an account of the research in the ASCO Post.
Advertisement
Advertisement
First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses
Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels
Findings highlight an association between obesity and an increased incidence of moderate-severe disease
Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access 23456
Key learnings from DESTINY trials
Gene editing technology offers promise for treating multiple myeloma and other hematologic malignancies, as well as solid tumors
Study of 401,576 patients reveals differences in cancer burdens as well as overall survival
Enfortumab plus pembrolizumab reduced risk of death by 53% compared with platinum-based chemotherapy